Zoetis (ZTS)
(Delayed Data from NYSE)
$159.70 USD
+1.28 (0.81%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $159.76 +0.06 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.70 USD
+1.28 (0.81%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $159.76 +0.06 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Zoetis (ZTS) closed at $171 in the latest trading session, marking a +1.9% move from the prior day.
Zoetis (ZTS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Zoetis (ZTS) closed at $165.18 in the latest trading session, marking a -1.82% move from the prior day.
UTHR vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. ZTS: Which Stock Is the Better Value Option?
COLL vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Top Research Reports for Berkshire Hathaway, Walmart, and P&G
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Walmart Inc. (WMT) and The Procter & Gamble Company (PG).
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
ASRT or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Why Is Ionis Pharmaceuticals (IONS) Down 16.4% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Procter & Gamble, Coca-Cola, The Progressive, Zoetis and Palo Alto Networks
by Zacks Equity Research
Procter & Gamble, Coca-Cola, The Progressive, Zoetis and Palo Alto Networks are part of the Zacks top Analyst Blog.
Top Stock Reports for Procter & Gamble, Coca-Cola & Progressive
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), The Coca-Cola Company (KO) and The Progressive (PGR).
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
by Zacks Equity Research
Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.
Zoetis (ZTS) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of -2.42% and 3.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More
by Kinjel Shah
Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.
Why Zoetis (ZTS) Might Surprise This Earnings Season
by Zacks Equity Research
Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.
Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Pet Industry Seems Recession-Proof: ETF & Stocks in Focus
by Sanghamitra Saha
American Pet Products Association, 70% of U.S. households own a pet, as quoted on Yahoo Finance. And Americans are splurging on their pets despite high inflation.
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
TAK vs. ZTS: Which Stock Is the Better Value Option?
TAK or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TAK vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Bank of America, Toyota Motor, AT&T, The Home Depot, Zoetis, and Occidental Petroleum
by Zacks Equity Research
Bank of America, Toyota Motor, AT&T, The Home Depot, Zoetis, and Occidental Petroleum are included in this Analyst Blog.